<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100165</url>
  </required_header>
  <id_info>
    <org_study_id>08-0837</org_study_id>
    <secondary_id>VISN 19 MIRECC</secondary_id>
    <nct_id>NCT00100165</nct_id>
  </id_info>
  <brief_title>Phase 2 Trial of a Nicotinic Agonist in Schizophrenia</brief_title>
  <acronym>DMXB-A</acronym>
  <official_title>Phase 2 Trial of the Nicotinic Agonist 3-(2,4 Dimethoxybenzylidene Anabaseine) in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that 3-2,4 dimethoxybenzylidene anabaseine (DMXB-A), an orally
      administered nicotinic cholinergic agonist, will improve attention and other
      neuropsychological dysfunctions in schizophrenia, leading to improved psychosocial outcome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the trial is to determine if dosing 3-(2,4 dimethoxybenzylidene anabaseine)
      twice daily for 4 weeks will improve cognition and be safe. Secondary goals are to determine
      if these neurocognitive effects also have effects on neurobiological paradigms previously
      shown to be responsive to nicotinic receptor stimulation: suppression of P50 auditory evoked
      response, saccadic intrusions during smooth pursuit eye movements, and hemodynamic activity
      in the hippocampus during smooth pursuit eye movements as measured by functional magnetic
      resonance imaging. The purpose of these neurobiological measures is to assess whether the
      response to 3-(2,4 dimethoxybenzylidene anabaseine) is consistent with activation of
      nicotinic receptors. In addition, the investigators will assess clinical response using a
      battery of clinical assessment scales and assessments of daily living functions. The purpose
      of these assessments is to address the FDA requirement of a clinical effect beyond change in
      laboratory neuropsychological performance. This study and the subsequent two studies will
      also include assessments of the safety of 3-(2,4 dimethoxybenzylidene anabaseine) and related
      compounds.

      The purpose of the trial is to lay the groundwork for Phase III investigation. If this trial
      finds that 3-(2,4 dimethoxybenzylidene anabaseine) has effects at a safe dose, without
      tachyphylaxis, then the investigators intend to proceed to a Phase III trial, where the
      clinical importance of this effect can be measured.

      The trial will be a double blind trial with placebo control. The order of doses and placebo
      will be randomized.

      The Phase 1 study was completed in January, 2005, with 12 non-smoking schizophrenics
      subjects. The subjects were concurrently treated with neuroleptics throughout the study. They
      received 3 treatments, each for 1 day, in a double-blind crossover design. The treatments
      were 3-(2,4 dimethoxybenzylidene anabaseine) (150 mg + 75 mg 2 hours later), 3-(2,4
      dimethoxybenzylidene anabaseine)(75 mg + 37.5 mg 2 hours later), and placebo. A significant
      effect on neurocognition, as measured by the Repeatable Battery for Assessment of
      Neuropsychological Status, and on sensory gating, as measured by P50 auditory evoked
      potentials was observed. Subjects reported no significant symptoms. One subject's white blood
      cell count decreased from just above normal limits on placebo to just below normal levels on
      3-(2,4 dimethoxybenzylidene anabaseine)(150 + 75 mg 2 hours later). He did not receive
      further exposure to drug and his white blood cell count returned to normal at the next
      testing, 2 days later.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurocognitive Performance</measure>
    <time_frame>1 month</time_frame>
    <description>The measurement of neurocognitive performance on 6 domains, speed of processing, attention/vigilance, working memory, verbal learning, visual learning and reasoning/problem solving. Each domain is compared to a normative sample of schizophrenia subjects and the performance is determined and compared by a T-Test to the subjects baseline performance to determine the effect of drug or placebo. The scale is the National Institute of Mental Health Measurement and Treatment Research to Improve Cognition in Schizophrenia Neurocognitive Consensus Combined Battery, range 0-100. A higher score indicates better performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Scale for the Assessment of Negative Symptoms (SANS)</measure>
    <time_frame>1 month</time_frame>
    <description>The Scale for the Assessment of Negative Symptoms measures the measure negative symptoms in schizophrenia by measuring the domains of anhedonia, alogia, avolition and anhedonia in schizophrenia on a scale from 1 to 20 that sums the global scores of all 4 domains, each of which are rated on a scale of 1-5. Higher scores indicate greater severity of negative symptoms</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>3-(2,4 dimethoxybenzylidene anabaseine) 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 150 mg twice per day in a blinded capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-(2,4 dimethoxybenzylidene anabaseine)75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives 3-(2,4 dimethoxybenzylidene anabaseine) 75 mg twice per day in a blinded capsule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient receives placebo twice per day in a blinded capsule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo by mouth twice a day for 4 weeks</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>inactive substance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3-(2,4 dimethoxybenzylidene anabaseine) 150 mg</intervention_name>
    <description>3-(2,4 dimethoxybenzylidene) 150 mg by mouth twice a day for 4 weeks</description>
    <arm_group_label>3-(2,4 dimethoxybenzylidene anabaseine) 150 mg</arm_group_label>
    <other_name>GTS-21</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3-(2,4 dimethoxybenzylidene anabaseine) 75 mg</intervention_name>
    <description>3-(2,4 dimethoxybenzylidene) 75 mg by mouth twice a day for 4 weeks</description>
    <arm_group_label>3-(2,4 dimethoxybenzylidene anabaseine)75 mg</arm_group_label>
    <other_name>GTS-21</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Schizophrenia

          -  Currently treated with neuroleptic drugs

        Exclusion Criteria:

          -  Treatment with clozapine;

          -  Head injury or neurological condition;

          -  Cardiovascular disease;

          -  Substance abuse or dependence, including nicotine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Freedman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Eastern Colorado Health Care System, Denver, CO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Eastern Colorado Health Care System, Denver, CO</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 23, 2004</study_first_submitted>
  <study_first_submitted_qc>December 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2004</study_first_posted>
  <results_first_submitted>August 24, 2016</results_first_submitted>
  <results_first_submitted_qc>January 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 29, 2020</results_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(2,4-dimethoxybenzylidene)anabaseine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirty-four subjects were screened. Two were excluded because of abnormal laboratory values and one was excluded for a recent hospitalization. Thirty-one subjects were enrolled at two sites: The University of Colorado, Denver/Denver VA Medical Center (25 subjects) and The Maryland Psychiatric Research Center 6 subjects.</recruitment_details>
      <pre_assignment_details>Subjects were administered 1 week of placebo to assess their ability to comply with BID dosing prior to administration of drug or placebo. There was a 1 week washout period between arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Then DMXB-A 75, Then DMXB-A 150</title>
          <description>Placebo then 3-(2,4-dimethoxybenzylidene) anabaseine 75 mg then 3-(2,4-dimethoxybenzylidene) anabaseine 150 mg</description>
        </group>
        <group group_id="P2">
          <title>DMXB-A 75, Then DMXB-A 150, Then Placebo</title>
          <description>3-(2,4-dimethoxybenzylidene) anabaseine 75 mg,then 3-(2,4-dimethoxybenzylidene) anabaseine 150 mg, then placebo</description>
        </group>
        <group group_id="P3">
          <title>DMXB-A 150 mg, Then Placebo, Then DMXB-A 75</title>
          <description>3-(2,4-dimethoxybenzylidene) anabaseine 150 mg, then placebo, then 3-(2,4-dimethoxybenzylidene) anabaseine 75 mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>First Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention (4 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DMXB-A 75, Then DMXB- 150, Then Placebo</title>
          <description>Overall number of baseline participants 10
Age, continuous</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then DMXB-A 75, Then DMXB-A 150</title>
          <description>Overall number of baseline participants 10
Age , continuous</description>
        </group>
        <group group_id="B3">
          <title>DMXB-A 150, Then Placebo, Then DMXB-A 75</title>
          <description>Overall number of baseline participants 9
Age, continuous</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="9"/>
            <count group_id="B4" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.1" spread="10.3"/>
                    <measurement group_id="B2" value="40.5" spread="9.8"/>
                    <measurement group_id="B3" value="43.2" spread="10.4"/>
                    <measurement group_id="B4" value="41.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Neurocognitive Performance</title>
        <description>The measurement of neurocognitive performance on 6 domains, speed of processing, attention/vigilance, working memory, verbal learning, visual learning and reasoning/problem solving. Each domain is compared to a normative sample of schizophrenia subjects and the performance is determined and compared by a T-Test to the subjects baseline performance to determine the effect of drug or placebo. The scale is the National Institute of Mental Health Measurement and Treatment Research to Improve Cognition in Schizophrenia Neurocognitive Consensus Combined Battery, range 0-100. A higher score indicates better performance.</description>
        <time_frame>1 month</time_frame>
        <population>change from baseline in cognitive performance as measured by a t-test at 4 weeks after taking the drug or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Change in t-score from baseline performance on neurocognitive measures when taking placebo for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>3-(2,4-dimethoxybenzylidene) Anabaseine 75 mg</title>
            <description>Change in t-scores from baseline neurocognitive performance when taking 3-(2,4-dimethoxybenzylidene) anabaseine 75 mg p.o. BID for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>3-(2,4-dimethoxybenzylidene) Anabaseine 150 mg</title>
            <description>Change in t-scores from baseline neurocognitive performance when taking3-(2,4-dimethoxybenzylidene) anabaseine 150 mg p.o BID for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neurocognitive Performance</title>
          <description>The measurement of neurocognitive performance on 6 domains, speed of processing, attention/vigilance, working memory, verbal learning, visual learning and reasoning/problem solving. Each domain is compared to a normative sample of schizophrenia subjects and the performance is determined and compared by a T-Test to the subjects baseline performance to determine the effect of drug or placebo. The scale is the National Institute of Mental Health Measurement and Treatment Research to Improve Cognition in Schizophrenia Neurocognitive Consensus Combined Battery, range 0-100. A higher score indicates better performance.</description>
          <population>change from baseline in cognitive performance as measured by a t-test at 4 weeks after taking the drug or placebo</population>
          <units>t-score change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="7.3"/>
                    <measurement group_id="O2" value="6.1" spread="9.4"/>
                    <measurement group_id="O3" value="7.6" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Scale for the Assessment of Negative Symptoms (SANS)</title>
        <description>The Scale for the Assessment of Negative Symptoms measures the measure negative symptoms in schizophrenia by measuring the domains of anhedonia, alogia, avolition and anhedonia in schizophrenia on a scale from 1 to 20 that sums the global scores of all 4 domains, each of which are rated on a scale of 1-5. Higher scores indicate greater severity of negative symptoms</description>
        <time_frame>1 month</time_frame>
        <population>change in the total scale score from baseline measure with administration of either drug or placebo</population>
        <group_list>
          <group group_id="O1">
            <title>3-2,4 Dimethoxybenzylidene 75 mg</title>
            <description>change in total scale for the assessment of negative symptoms at baseline after taking 3-2,4 dimethoxybenzylidene 75 mg BID for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>3-2,4 Dimethoxybenzylidene 150 mg</title>
            <description>change in total scale for the assessment of negative symptoms at baseline after taking 3-2,4 dimethoxybenzylidene BID 150 mg for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>change in total scale for the assessment of negative symptoms at baseline after taking placebo BID for 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Scale for the Assessment of Negative Symptoms (SANS)</title>
          <description>The Scale for the Assessment of Negative Symptoms measures the measure negative symptoms in schizophrenia by measuring the domains of anhedonia, alogia, avolition and anhedonia in schizophrenia on a scale from 1 to 20 that sums the global scores of all 4 domains, each of which are rated on a scale of 1-5. Higher scores indicate greater severity of negative symptoms</description>
          <population>change in the total scale score from baseline measure with administration of either drug or placebo</population>
          <units>units on a scale change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="9.4"/>
                    <measurement group_id="O2" value="7.6" spread="10.6"/>
                    <measurement group_id="O3" value="4.6" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Four weeks for each intervention</time_frame>
      <desc>Safety population included all participants who received at least one dose of intervention</desc>
      <group_list>
        <group group_id="E1">
          <title>DMXB-A 75 mg</title>
          <description>3-(2,4 dimethoxybenzylidene) 75 mg p.o. BID for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>DMXBA 150 mg</title>
          <description>3-(2,4 dimethoxybenzylidene) 150 mg p.o. BID for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo p.o. BID for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>visual changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>malaise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>drooling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>change in taste</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>diaphoresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>limb pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>restlessness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>stiffness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="29"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>parasthesias</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>nervousness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>hallucinations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>delusions</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="29"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>enuresis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert Freedman</name_or_title>
      <organization>University of Colorado, Denver</organization>
      <phone>303 724-4940</phone>
      <email>robert.freedman@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

